UK markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.9200-0.0150 (-0.78%)
As of 11:39AM EDT. Market open.

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees240

Key executives

NameTitlePayExercisedYear born
Mr. Sheldon L. KoenigPresident, CEO & Director1.2MN/A1966
Mr. Benjamin Halladay M.B.A.Chief Financial OfficerN/AN/A1986
Mr. Glenn P. BrameChief Technical Operations OfficerN/AN/A1958
Tiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsN/AN/AN/A
Ms. Betty Jean SwartzChief Business OfficerN/AN/AN/A
Mr. Eric J. Warren R.Ph.Chief Commercial OfficerN/AN/A1972
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate governance

Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.